Haemonetics (NYSE:HAE) Shares Gap Down – What’s Next?

Haemonetics Corporation (NYSE:HAE) shares gapped down prior to trading on Thursday . The stock had previously closed at $78.82, but opened at $75.51. Haemonetics shares last traded at $75.4550, with a volume of 15,631 shares trading hands.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Citigroup dropped their target price on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Barrington Research boosted their target price on shares of Haemonetics from $90.00 to $93.00 and gave the company an “outperform” rating in a report on Monday. Needham & Company LLC downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. Finally, CJS Securities raised shares of Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.40.

Haemonetics Trading Down 2.4%

The firm has a fifty day moving average of $79.37 and a 200-day moving average of $66.02. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. The stock has a market capitalization of $3.46 billion, a price-to-earnings ratio of 21.59, a P/E/G ratio of 1.49 and a beta of 0.29.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The business had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. During the same period last year, the business posted $1.12 EPS. The company’s revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. True Wealth Design LLC increased its holdings in Haemonetics by 6,700.0% during the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 335 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 165 shares in the last quarter. UMB Bank n.a. grew its position in shares of Haemonetics by 91.7% during the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 320 shares in the last quarter. Finally, Versant Capital Management Inc raised its holdings in Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 567 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.